Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

• Yu-Ting Ma,
• Yan Li,
• Li Yan,
• Fang Hua,
• Dong-Guan Wang,
• Guo-Ying Xu,
• Hong-Lan Yang,
• Ying-Jie Xue,
• Ye-Jun Qin,
• Dan Sha,
• Hao Ning,
• Miao-Qing Zhao,
• Zhi-Gang Yao

Affiliations

Yu-Ting Ma

Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Yan Li

Departmentof Oncology, Dongying City People’s Hospital, Dongying, China

Li Yan

Department of Pathology, Dongying City People’s Hospital, Dongying, China

Fang Hua

Department of Microbiology and Immunology, Tulane University, New Orleans, LA, United States

Dong-Guan Wang

Department of Pathology, Dongying City People’s Hospital, Dongying, China

Guo-Ying Xu

Department of Urology Surgery, Dongying Hospital of Traditional Chinese Medicine, Dongying, China

Hong-Lan Yang

Departmentof Oncology, Dongying City People’s Hospital, Dongying, China

Ying-Jie Xue

Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Ye-Jun Qin

Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Dan Sha

Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Hao Ning

Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Miao-Qing Zhao

Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

Zhi-Gang Yao

Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China